Multiunit Particulate Systems: A Current Drug-Delivery Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Multiunit Particulate Systems: A Current Drug-Delivery Technology
The current review describes the role and selection of excipients, pellet core, coating materials, and compression with various cushioning agents.


Pharmaceutical Technology
Volume 35, Issue 7, pp. 60-66

References

1. N.S. Dey, S. Majumdar, and M.E.B. Rao, Trop. J. Pharm. Res. 7 (3), 1067–1075 (2008).

2. N. Follonier and E. Doelker, S.T.P. Pharma Sci. 2 (2), 141–158 (1992).

3. A.S. Abdul, A.V. Chandewar, and S.B. Jaiswal, J. Control. Release 147 (1), 2–16 (2010).

4. FASS 2002, A.G. Hedstrand, Ed. (LINFO, Stockholm, 2002), pp. 853–854.

5. R. Bodmeier, Eur. J. Pharm. Biopharm. 43 (1), 1–8 (1997).

6. A.E.K. Lundqvist, F. Podczeck, and J.M. Newton, Eur. J. Pharm. Biopharm. 46 (3), 369–379 (1998).

7. H. Leuenberger, Int. J. Pharm. 12 (1), 41–55 (1982).

8. C. Sun and D.J.W. Grant, Pharm. Dev. Technol. 6 (2), 193–200 (2001).

9. J. Van der Zwan and C.A.M. Siskens, Powder Technol. 33 (1), 43–54 (1982).

10. B. Johansson and G. Alderborn, Int. J. Pharm. 132 (1–2), 207–220 (1996).

11. J.B. Schwartz, N.H. Nguyen, and R.L. Schnaare, Drug Dev. Ind. Pharm. 20 (20), 3105–3129 (1994).

12. F. Nicklasson and G. Alderborn, Eur. J. Pharm. Sci. 9 (1), 57–65 (1999).

13. C. Wang et al., Drug Dev. Ind. Pharm. 21 (7), 753–779 (1995).

14. N.O. Iloanusi and J.B. Schwartz, Drug Dev. Ind. Pharm. 24 (1), 37–44 (1998).

15. M. Salako, F. Podczeck, and J.M. Newton, Int. J. Pharm. 168 (1), 49–57 (1998).

16. M.E. Aulton, A.M. Dyer, and K.A. Khan, Drug Dev. Ind. Pharm. 20 (20), 3069–3104 (1994).

17. J.L. Haslam et al., Int. J. Pharm. 173 (1–2), 233–242 (1998).

18. B. Johansson, F. Nicklasson, and G. Alderborn, Int. J. Pharm. 163 (1–2), 35–48 (1998).

19. N Sarisuta and K. Punpreuk, J. Control. Release 31 (3), 215–222 (1994).

20. S.C. Porter, Drug Dev. Ind. Pharm. 15 (10), 1495–1521 (1989).

21. M.P. Flament et al., Pharm. Technol. Eur. 6 (2), 19–25 (1994).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here